Titan's proprietary long-term, drug delivery platform provides continuous drug release and non-fluctuating medication levels over a period of three months to a year depending on drug characteristics. ProNeura products are subdermal implants that are ideal for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration.
ProNeura offers continuous drug delivery and consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period.
This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6 to 12 months.
The drug substance that is part of the ProNeura implant is released slowly into the patient's body at continuous levels, through the process of dissolution. This results in a stable level of medication in the blood, similar to intravenous administration. Such long-term, linear release characteristics are generally desirable, as this avoids peak-and-trough level dosing that poses problems in the treatment of several chronic diseases.
In the case of Probuphine®, the ProNeura implant contains 80 mg of buprenorphine HCl, uniformly distributed throughout the EVA matrix.
for the treatment of Opioid Addiction
|
Market completed
|
Market completed
|
Market completed
|
Market completed
|
Market in progress
|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|
for the treatment of Parkinson's Disease
|
Phase 1 completed
|
Phase 1 in progress
|
Phase 1 not started
|
Phase 1 not started
|
Phase 1 not started
|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|
for the treatment of Hypothyroidism
|
Preclinical in progress
|
Preclinical not started
|
Preclinical not started
|
Preclinical not started
|
Preclinical not started
|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|
